# 168000

PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 1; PPGL1


Alternative titles; symbols

PARAGANGLIOMAS 1; PGL1
PARAGANGLIOMAS, FAMILIAL, 1
PARAGANGLIOMATA; PGL
GLOMUS TUMORS, FAMILIAL, 1
CHEMODECTOMAS
CAROTID BODY TUMORS; CBT1
GLOMUS JUGULARE TUMORS
PARAGANGLIOMA, CAROTID BODY
PARAGANGLIOMAS, FAMILIAL NONCHROMAFFIN, 1


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
11q23.1 Pheochromocytoma/paraganglioma syndrome 1 168000 AD 3 SDHD 602690
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
HEAD & NECK
Ears
- Pulsatile tinnitus (tympanic paraganglioma)
- Conductive hearing loss (in a subset of patients)
CARDIOVASCULAR
Heart
- Palpitations (with pheochromocytoma)
- Tachycardia (with pheochromocytoma)
Vascular
- Hypertension (with pheochromocytoma)
RESPIRATORY
Larynx
- Vocal cord paralysis (caused by tumor impingement)
SKIN, NAILS, & HAIR
Skin
- Diaphoresis (with pheochromocytoma)
NEUROLOGIC
Central Nervous System
- Headache (with pheochromocytoma)
- Cranial nerve palsies can arise with head and neck paragangliomas
Behavioral Psychiatric Manifestations
- Anxiety (with pheochromocytoma)
VOICE
- Hoarse voice (caused by tumor impingement)
- Loss of voice
NEOPLASIA
- Paragangliomas
- Multiple tumors in 74% of patients
- Paragangliomas, head and neck (79%)
- Chemodectomas
- Carotid body tumors (most common location)
- Glomus jugular tumors
- Vagal nerve tumors (glomus vagale)
- Tympanic nerve tumors (glomus tympanicum)
- Pheochromocytoma, adrenal (53%)
- Pheochromocytoma, extraadrenal (21%)
LABORATORY ABNORMALITIES
- Elevated catecholamines (in patients with pheochromocytoma)
MISCELLANEOUS
- Cells of origin are part of the diffuse neuroendocrine system (DNES)
- Adult onset (mean 30 years, range 5-60 years)
- Maternal imprinting
- Penetrance 86% by 50 years of age
- Signs and symptoms depend on tumor location and activity
- Patients may have head and neck paragangliomas only, adrenal or extraadrenal pheochromocytomas only, or both
- See also PGL2 (601650), PGL3 (605373), and PGL4 (115310)
MOLECULAR BASIS
- Caused by mutations in the succinate dehydrogenase complex subunit D gene (SDHD, 602690.0001)

TEXT

A number sign (#) is used with this entry because of evidence that pheochromocytoma/paraganglioma syndrome-1 (PPGL1) is caused by heterozygous mutation in the SDHD gene (602690), which encodes the small subunit of cytochrome B in succinate-ubiquinone oxidoreductase, on chromosome 11q23.


Description

Pheochromocytoma/paraganglioma syndrome-1 (PPGL1) is an autosomal dominant disorder characterized by the development of neuroendocrine tumors, usually in adulthood. Pheochromocytomas arise from chromaffin cells in the adrenal medulla, whereas paragangliomas arise in extra-adrenal sympathetic ganglia in the thorax, abdomen, and pelvis or from parasympathetic paraganglia in the head and neck area (summary by Cascon et al., 2023).

Paragangliomas, also referred to as 'glomus body tumors,' are tumors derived from paraganglia located throughout the body. Nonchromaffin types primarily serve as chemoreceptors (hence, the tumor name 'chemodectomas') and are located in the head and neck region (i.e., carotid body, jugular, vagal, and tympanic regions), whereas chromaffin types have endocrine activity, conventionally referred to as 'pheochromocytomas,' and are usually located below the head and neck (i.e., adrenal medulla and pre- and paravertebral thoracoabdominal regions). PPGL can manifest as nonchromaffin head and neck tumors only, adrenal and/or extraadrenal pheochromocytomas only, or a combination of the 2 types of tumors (Baysal, 2002; Neumann et al., 2004).

The triad of gastric leiomyosarcoma, pulmonary chondroma, and extraadrenal paraganglioma constitutes a syndrome that occurs mainly in young women and is known as the Carney triad (604287). This triad is not to be confused with the other Carney syndrome of myxoma, spotty pigmentation, and endocrinopathy (160980).

Baysal (2008) provided a review of the molecular pathogenesis of hereditary paraganglioma.

Genetic Heterogeneity of Pheochromocytoma/Paraganglioma Syndrome

See also PPGL2 (601650), caused by mutation in the SDHAF2 gene (613019) on chromosome 11q13; PPGL3 (605373), caused by mutation in the SDHC gene (602413) on chromosome 1q21; PPGL4 (115310), caused by mutation in the SDHB gene (185470) on chromosome 1p36; PPGL5 (614165), caused by mutation in the SDHA gene (600857) on chromosome 5p15; PPGL6 (618464), caused by mutation in the SLC25A11 gene (604165) on chromosome 17p13; and PPGL7 (618475), caused by mutation in the DLST gene (126063) on chromosome 14q24.


Clinical Features

Kroll et al. (1964) found carotid body tumors in 12 members of a family in an autosomal dominant pattern of inheritance. Resler et al. (1966) reported a patient with bilateral carotid body tumors and a glomus jugulare tumor. The authors noted that familial carotid body tumors tended to be multiple. Familial glomus jugulare tumors were likely described in 3 affected sisters reported in 1937 by Goekoop (cited by Rosen, 1952). Also see Ladenheim and Sachs (1961). Bartels (1949) identified carotid body tumors in members of 3 successive generations of a family.

Wilson (1970) reviewed familial reports of carotid body tumors and described a family with male-to-male transmission and a skipped generation. Pratt (1973) reviewed the literature and reported 8 new cases of either unilateral or bilateral carotid body tumors in 4 generations of a kindred. In 1 generation of this family, 4 sisters had bilateral tumors and 1 brother had unilateral tumors. None of the 8 tumors reported were malignant. Chedid and Jao (1974) identified carotid body tumors in 6 members of 2 consecutive generations of a family. Four also had chronic obstructive pulmonary disease with persistently high arterial pCO(2) and low pO(2). The authors theorized that the tumors started as hyperplasia secondary to the stimulus of these altered blood gases. Nissenblatt (1978) reported a young woman with hypoplastic right heart syndrome who developed a carotid body tumor at age 28 years. He suggested a connection between low-oxygen situations such as high altitude living, emphysema, and cyanotic congenital heart disease, and the development of carotid body tumors.

Grufferman et al. (1980) reported 2 sisters with carotid body tumors and reviewed reports of 88 familial and 835 nonfamilial CBT cases. Familial cases had an equal sex ratio and followed autosomal dominant inheritance. Bilateral disease occurred in 31.8% of familial cases and 4.4% of sporadic cases. Six percent of all patients developed second primary tumors, mostly other paragangliomas. Parry et al. (1982) reviewed the records of 222 histologically diagnosed cases of carotid body tumors, including 146 females and 76 males. The mean age at tumor development was 44.7 years. In 16 patients who had other extraadrenal paragangliomas, suggesting a multiple primary tumor syndrome, the diagnosis occurred earlier (mean, 35.4 years; p less than 0.01). Five patients also developed thyroid cancer. Familial cases were more often bilateral and diagnosed slightly earlier.

Van Baars et al. (1982) provided a review of the literature of familial nonchromaffin paragangliomas. Carotid body tumors were the most common, followed by glomus jugulare, glomus vagale, and glomus tympanicum.

Parkin (1981) reported 2 unrelated families with a hereditary syndrome of pheochromocytoma associated with multiple glomus tumors of the head and neck. DeAngelis et al. (1987) reported the occurrence of pheochromocytoma and multiple paragangliomas in a patient with neurofibromatosis (162200). Karasov et al. (1982) described a sporadic case of a girl with a record number of 21 paragangliomas removed between the ages of 13 and 17 years, with evidence of remaining tumors. The tumors were catecholamine-producing. Khafagi et al. (1987) reported 2 unrelated adults, both of whom had a positive family history of paraganglioma. Both had malignant nonfunctional paragangliomas detected by uptake of iodine-131 metaiodobenzylguanidine; this agent proved to be of therapeutic value in the management of unresectable metastases.

Van Schothorst et al. (1998) reported 10 families with head and neck paragangliomas who originated from the same geographic region in the Netherlands. The carotid bifurcation was the most frequently affected site (57% of all head and neck tumors), and multiple paragangliomas occurred in 66% of patients. Three patients from different families developed a pheochromocytoma. No affected offspring of female carriers was observed, and all affected family members received the disease gene from their father.

Prontera et al. (2008) reported an Italian family with PGL1. The proband was a 49-year-old man who presented with throat pain, dysphonia, dyspnea, and mild hypertension, and was found to have bilateral carotid chemodectomas with multiple highly vascularized laryngeal and carotid paragangliomas. Family history revealed that the father, who died at age 71 of lung cancer, was diagnosed at age 66 with bilateral paragangliomas in the pericarotid region. The 55-year-old sister of the proband developed multiple laryngeal and carotid paragangliomas at age 52. The proband and his sister both carried a heterozygous truncating mutation in the SDHD gene.

Hensen et al. (2010) used the Kaplan-Meier method to calculate the age-specific penetrance of paragangliomas in 243 members of a large 7-generation Dutch family (Oosterwijk et al., 1996) with PGL1 caused by a founder mutation in the SDHD gene (D92Y; 602690.0004). The age at onset of symptoms ranged from 14 to 47 years. By clinical signs and symptoms alone, the penetrance reached a maximum of 57% by age 47 years. When MRI detection of occult paragangliomas was included, penetrance was estimated at 54% by age 40, 68% by age 60, and 87% by age 70. Multiple tumors were found in 65%, and 8% of paraganglioma patients had pheochromocytomas. One (3%) patient developed a malignant paraganglioma. None of 11 instances of maternal transmission of the mutation resulted in the development of paragangliomas. The findings indicated that the majority of mutation carriers will eventually develop head and neck paragangliomas, although Hensen et al. (2010) stated that the penetrance in this study was lower than some previous estimates. Hensen et al. (2010) emphasized the importance of including clinically unaffected mutation carriers in estimates of penetrance.

Among 47 asymptomatic carriers of SDHD mutations screened by physical examination or MRI, Heesterman et al. (2013) found that 28 (59.6%) carried a total of 57 tumors, including 38 carotid body tumors, 17 vagal body tumors, and 2 jugulotympanic tumors. Multiple tumors were seen in 34% of patients. Two patients (4.3%) had a sympathetic paraganglioma. The report indicated that a high percentage of asymptomatic SDHD mutation carriers have occult head and neck paragangliomas.


Inheritance

Maternal Imprinting

From a study of 15 pedigrees, van der Mey et al. (1989) concluded that familial paragangliomas, which they referred to as hereditary glomus tumors, were inherited almost exclusively through the paternal line, a finding inconsistent with simple autosomal dominant transmission. They suggested a role for genomic imprinting, in which the maternally derived gene is inactivated during female oogenesis and can be reactivated only during spermatogenesis. Heutink et al. (1992) stated that all individuals with hereditary paragangliomas had inherited the disease gene from their father; expression of the phenotype was not observed in the offspring of an affected female until subsequent transmission of the gene through a male carrier. The observations strongly suggested genomic imprinting.

Baysal et al. (1997) noted that the age of onset of symptoms was significantly different between fathers and children: affected children had an earlier age of onset in 39 of 57 father-child pairs.

Maternal Inheritance

Pigny et al. (2008) reported what they believed to be the first description of a paraganglioma kindred with maternal transmission of the mutated SDHD (602690) allele. A boy received the W43X mutation (602690.0023) from his mother and developed a glomus tympanicum paraganglioma at 11 years of age. He shared only the 11q23 haplotype with the other affected members of the family. Pigny et al. (2008) concluded that maternal transmission of a SDHD-linked paraganglioma, even if a rare event, can occur.


Mapping

In a large Dutch pedigree with hereditary paragangliomas, Heutink et al. (1992) found linkage with marker D11S147 located at chromosome 11q23-qter (maximum lod score of 6.0 at theta = 0.0 ). Likelihood calculations yielded a very high odds ratio in favor of genomic imprinting versus absence of genomic imprinting. Devilee et al. (1992) performed haplotyping in this large Dutch family using 15 markers in the region 11q13-q23. Two recombination events placed the PGL locus distal to STMY (185260) and proximal to D11S836, thus excluding the oncogenes INT2 (164950) and ETS1 (164720) as the site of the mutation. In an affected PGL family that showed imprinting, Mariman et al. (1995) found linkage to the locus on distal 11q.

In patients with familial nonchromaffin paragangliomas, Devilee et al. (1994) found loss of heterozygosity (LOH) only on chromosome 11, with a marked clustering on the distal half of the long arm. In all 8 cases in which they could determine the parental origin, the allele undergoing loss was maternally derived. However, LOH in all tumors was only partial, and it was not clear whether this represented an allelic imbalance or cellular heterogeneity. In a later study, van Schothorst et al. (1998) performed LOH analysis for the 11q22-q23 region on DNA-aneuploid tumor cells, enriched by flow sorting, and on purified chief cell fractions obtained by single-cell microdissection. Complete LOH was found in both types of cells, indicating that the chief cells were clonal proliferated tumor cells.

Oosterwijk et al. (1996) gave the location of the PGL1 gene as 11q22.3-q23. They offered genetic counseling on the basis of DNA linkage diagnosis in an extended Dutch pedigree. Presymptomatic testing of the paternal allele was performed in 16 cases; 4 of these appeared to have the at-risk haplotype and in 2 of the 4 a glomus tumor was subsequently detected on MRI. In 1 case linkage results were inconclusive because of recombination and 1 person did not want to learn his test result. The maternal allele was tested for carrier status in 4 cases of which 1 appeared to be a carrier.

Baysal et al. (1997) reported linkage of paraganglioma to chromosome 11q23 in 3 of 6 North American families. Recombinants narrowed the critical region to a 4.5-Mb interval flanked by the markers D11S1647 and D11S622. Partial allelic loss of strictly maternal origin was detected in 5 of 19 tumors. Milunsky et al. (1997) confirmed linkage to 11q23 in studies of 3 affected families. The inheritance pattern was consistent with genetic imprinting; the disorder was transmitted only by males.

Another 10 families with hereditary head and neck paragangliomas were ascertained by van Schothorst et al. (1998) from the same geographic region as that from which the large PGL1-linked Dutch family originated (Heutink et al., 1992). They determined the disease-linked haplotype, as defined by 13 markers encompassing a large interval on 11q21-q23, in these families and showed that alleles were identical for 6 contiguous markers spanning a genetic distance of 6 cM and containing PGL1. Despite this strong indication of a common ancestor, no kinship between the families could be demonstrated through genealogic surveys going back to 1800. Baysal et al. (1999) reevaluated the haplotype data of the multigenerational Dutch PGL1-linked family, using 2 additional single tandem repeat polymorphisms (STRPs) contained within the PGL1 critical interval proposed by van Schothorst et al. (1998). They excluded this interval, and instead predicted a nonoverlapping, more proximal 2-Mb critical interval between markers D11S1647 and D11S897. Analysis of 4 new American PGL families defined the telomeric border of the critical region as D11S1347. Among 3 unrelated American PGL families, significant haplotype sharing within this new interval was observed, strongly suggesting that they originated from a common ancestor. In sum, the authors refined the PGL1 locus to a 1.5-Mb region between D11S1986 and D11S1347.


Molecular Genetics

Astrom et al. (2003) stated that a large number of PGL1 families had been reported from the Netherlands and that there may be Dutch founder mutations.

In affected members of families with hereditary paraganglioma, Baysal et al. (2000) identified mutations in the SDHD gene (602690.0001-602690.0005), including the Dutch founder mutation (D92Y; 602690.0004).

Gimm et al. (2000) identified several mutations in the SDHD gene in unrelated patients. One patient had a pheochromocytoma and a carotid body paraganglioma (see 602690.0010); 2 unrelated patients, 1 with an extraadrenal intraabdominal pheochromocytoma with involvement of the jugular fossa, suggesting malignancy, and 1 with an isolated intestinal lipoma, had the same mutation (602690.0011); and a 33-year-old woman had 2 extraadrenal pheochromocytomas, 1 intraabdominal and 1 intrathoracic (see 602690.0002). Finally, the authors identified a somatic SDHD mutation in a pheochromocytoma (602690.0003).

In 7 families with familial paragangliomas, Milunsky et al. (2001) identified mutations in the SDHD gene (602690.0006-602690.0009). Three unrelated families had the same mutation (602690.0003), suggesting a founder effect. A restriction enzyme assay was developed for initial screening for the common mutation.

Cascon et al. (2002) performed mutation analysis of the SDHD gene in 25 consecutive, unrelated patients with pheochromocytoma and/or paraganglioma, with or without family history. There were 18 patients with pheochromocytoma, 4 with paraganglioma alone, and 3 with both, who had tested negative for germline mutations in the VHL (608537) and RET (164761) genes. Two novel truncating mutations were detected, a 4-bp deletion (602690.0022) in an apparently sporadic case of paraganglioma and pheochromocytoma, and a nonsense mutation (602690.0023) in a patient with paraganglioma with a family history of pheochromocytoma.

In a patient of German descent with sporadic bilateral carotid body paragangliomata, Leube et al. (2004) identified a frameshift mutation in the SDHD gene (602690.0020).

Mhatre et al. (2004) performed a mutation screen of the SDHB, SDHC, and SDHD genes in blood and tumor samples of 14 sporadic and 3 familial cases of head and neck paragangliomas. Germline mutations in SDHB and SDHD were identified in 2 of the 3 affected individuals with familial PGL, whereas no germline or somatic mutations were identified in the 14 sporadic cases. The presence of mutations within SDHB and SDHD in 2 of the 3 samples of familial PGL and absence of mutations in sporadic cases is consistent with a significant contribution of these genes to familial but not sporadic PGL.


Heterogeneity

Carotid Body Paragangliomas with Sensorineural Hearing Loss

Badenhop et al. (2001) studied 4 families with familial carotid body paragangliomas, 2 of which exhibited coinheritance of paragangliomas and sensorineural hearing loss or tinnitus. Sequence analysis identified mutations in exon 1 and exon 3 of the SDHD gene, including a novel 2-bp deletion in exon 3 creating a premature stop codon at position 67 (602690.0013); a novel 3-bp deletion in exon 3 resulting in the loss of tyr93 (602690.0014); a missense mutation in exon 3 resulting in a pro81-to-leu substitution (602690.0003); and a novel G-to-C substitution in exon 1 resulting in a met1-to-val substitution (602690.0015). The PGL1 region contains another gene, DPP2/TIMM8B (606659), a homolog of the X-linked TIMM8A gene (300356), mutations in which cause dystonia and deafness seen in Mohr-Tranebjaerg syndrome (304700). The authors found no base changes in the TIMM8B gene; thus, it would seem that the association of paraganglioma with sensorineural hearing loss cannot be explained by the proximity of the TIMM8B and SDHD genes.


Genotype/Phenotype Correlations

In a review of several studies, Baysal et al. (2002) found that 83 cases of paragangliomas-1 in 'unrelated' families and patients were attributable to 3 founder populations in the Netherlands, in stark contrast to 25 distinct SDHD mutations reported among 43 independent familial and nonfamilial cases in other parts of the world. Astrom et al. (2003) interpreted this finding as suggesting that low altitudes in the Netherlands reduce penetrance and relax the natural selection on SDHD mutations. They studied the influence of altitude on the phenotype of PGL1 in 58 patients from 23 families. Patients who were diagnosed with single tumors at their first clinical evaluation lived at lower average altitudes and were exposed to lower altitude-years than those with multiple tumors (p less than 0.012). Nonsense/splicing mutation carriers developed symptoms 8.5 years earlier than missense mutation carriers (p less than 0.012). Pheochromocytomas developed in 6 patients, 5 of whom had nonsense mutations. Patients with pheochromocytomas also lived at higher average altitudes and were exposed to higher altitude-years than those without them. Astrom et al. (2003) concluded that collectively, these data suggested that higher altitudes and nonsense/splicing mutations are associated with increased severity in PGL1 and supported the hypothesis that SDHD mutations impair oxygen sensing.

In a population-based genetic study of 334 unrelated patients with adrenal or extraadrenal pheochromocytomas and 83 patients with head and neck paragangliomas, Neumann et al. (2004) found that 12% of patients had a mutation in either the SDHB or SDHD gene, with equal distribution between the 2 genes (25 and 24 patients with mutations in the SDHB and SDHD genes, respectively). Mean age at diagnosis was similar between the 2 groups (approximately 30 years). Inheritance of SDHD mutations was consistent with maternal imprinting. Examination of relatives yielded a total of 32 and 34 manifesting carriers of SDHB and SDHD mutations, respectively. Multiple tumors occurred in 28% of SDHB carriers and 74% of SDHD carriers; adrenal pheochromocytomas occurred in 28% of SDHB carriers and 53% of SDHD carriers, whereas extraadrenal pheochromocytomas were identified in 48% of SDHB carriers and 21% of SDHD carriers; head and neck paragangliomas occurred in 31% of SDHB carriers and 79% of SDHD carriers; and malignancy occurred in 34% of SDHB carriers but no SDHD carriers. Two related SDHB carriers had renal cell carcinoma, and 1 SDHB and 1 SDHD carrier each had papillary thyroid carcinoma. Age-related penetrance for carriers of the 2 mutations was similar: SDHB and SDHD carriers showed 77% and 86% penetrance by age 50 years, respectively.

Benn et al. (2006) determined genotype/phenotype associations in a cohort of patients with pheochromocytoma/paraganglioma syndromes and SDHB or SDHD mutations. SDHB mutation carriers were more likely than SDHD mutation carriers to develop extraadrenal pheochromocytomas and malignant disease, whereas SDHD mutation carriers had a greater propensity to develop head and neck paragangliomas and multiple tumors. For the index cases, there was no difference between 43 SDHB and 19 SDHD mutation carriers in the time to first diagnosis (34 vs 28 years, respectively; p = 0.3). However, when all 112 mutation carriers were included, the estimated age-related penetrance was different for SDHB versus SDHD mutation carriers (p = 0.008).


Population Genetics

Hensen et al. (2012) determined the mutation frequency of 4 succinate dehydrogenase genes in a total of 1,045 patients from 340 Dutch families with paraganglioma and pheochromocytoma. Mutations were identified in 690 cases from 239 families. The most commonly affected gene in mutation carriers was SDHD (87.1%), followed by SDHAF2 (6.7%), SDHB (5.9%), and SDHC (0.3%). Almost 70% of all carriers had the founder mutation D92Y (602690.0004) in SDHD; approximately 89% of all SDH mutation carriers had 1 of 6 Dutch founder mutations. The dominance of SDHD mutations was unique to the Netherlands, contrasting with the higher prevalence of SDHB mutations found elsewhere.


Nomenclature

Strauchen (2002) noted that the interchangeable use of 'paraganglioma' and 'glomus tumor' was a 'common point of confusion.' He emphasized that the glomus tumor is a tumor of modified perivascular smooth muscle, which frequently presents as a painful subungual mass, and is unrelated to tumors of the adrenal and extraadrenal paraganglia. Jugulotympanic paraganglioma is often referred to as a 'glomus jugulare tumor.' This tumor arises from minute, anatomically dispersed paraganglia located at the base of the skull and temporal bone and is closely related to similar tumors of the carotid body and other extraadrenal paraganglia. It is unrelated to the much more common glomus tumor of skin and soft tissue. See 138000 for an inherited form of smooth muscle tissue glomus tumors.


History

The glomus jugulare was first discovered by Stacy R. Guild at Johns Hopkins in 1941 (Guild (1941, 1953)).


REFERENCES

  1. Astrom, K., Cohen, J. E., Willett-Brozick, J. E., Aston, C. E., Baysal, B. E. Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum. Genet. 113: 228-237, 2003. [PubMed: 12811540, related citations] [Full Text]

  2. Badenhop, R. F., Cherian, S., Lord, R. S. A., Baysal, B. E., Taschner, P. E. M., Schofield, P. R. Novel mutations in the SDHD gene in pedigrees with familial carotid body paraganglioma and sensorineural hearing loss. Genes Chromosomes Cancer 31: 255-263, 2001. [PubMed: 11391796, related citations] [Full Text]

  3. Bartels, J. De tumoren van het glomus jugulare. Thesis: Groningen (pub.) 1949.

  4. Baysal, B. E., Farr, J. E., Rubinstein, W. S., Galus, R. A., Johnson, K. A., Aston, C. E., Myers, E. N., Johnson, J. T., Carrau, R., Kirkpatrick, S. J., Myssiorek, D., Singh, D., Saha, S., Gollin, S. M., Evans, G. A., James, M. R., Richard, C. W., III. Fine mapping of an imprinted gene for familial nonchromaffin paragangliomas, on chromosome 11q23. Am. J. Hum. Genet. 60: 121-132, 1997. [PubMed: 8981955, related citations]

  5. Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., van der May, A., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., Richard, C. W., III, Cornelisse, C. J., Devilee, P., Devlin, B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287: 848-851, 2000. [PubMed: 10657297, related citations] [Full Text]

  6. Baysal, B. E., van Schothorst, E. M., Farr, J. E., Grashof, P., Myssiorek, D., Rubinstein, W. S., Taschner, P., Cornelisse, C. J., Devlin, B., Devilee, P., Richard, C. W., III. Repositioning the hereditary paraganglioma critical region on chromosome band 11q23. Hum. Genet. 104: 219-225, 1999. [PubMed: 10323245, related citations] [Full Text]

  7. Baysal, B. E., Willett-Brozick, J. E., Lawrence, E. C., Drovdlic, C. M., Savul, S. A., McLeod, D. R., Yee, H. A., Brackmann, D. E., Slattery, W. H., III, Myers, E. N., Ferrell, R. E., Rubinstein, W. S. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J. Med. Genet. 39: 178-183, 2002. [PubMed: 11897817, related citations] [Full Text]

  8. Baysal, B. E. Hereditary paraganglioma targets diverse paraganglia. J. Med. Genet. 39: 617-622, 2002. [PubMed: 12205103, related citations] [Full Text]

  9. Baysal, B. E. Clinical and molecular progress in hereditary paraganglioma. J. Med. Genet. 45: 689-694, 2008. [PubMed: 18978332, related citations] [Full Text]

  10. Benn, D. E., Gimenez-Roqueplo, A.-P., Reilly, J. R., Bertherat, J., Burgess, J., Byth, K., Croxson, M., Dahia, P. L. M., Elston, M., Gimm, O., Henley, D., Herman, P., and 9 others. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocr. Metab. 91: 827-836, 2006. [PubMed: 16317055, related citations] [Full Text]

  11. Cascon, A., Calsina, B., Monteagudo, M., Mellid, S., Diaz-Talavera, A., Curras-Freixes, M., Robledo, M. Genetic bases of pheochromocytoma and paraganglioma. J. Molec. Endocr. 70: e220167, 2023. [PubMed: 36520714, related citations] [Full Text]

  12. Cascon, A., Ruiz-Llorente, S., Cebrian, A., Telleria, D., Rivero, J. C., Diez, J. J., Lopez-Ibarra, P., Jaunsolo, M. A., Benitez, J., Robledo, M. Identification of novel SDHD mutations in patients with phaeochromocytoma and/or paraganglioma. Europ. J. Hum. Genet. 10: 457-461, 2002. [PubMed: 12111639, related citations] [Full Text]

  13. Chase, W. H. Familial and bilateral tumours of the carotid body. J. Path. Bact. 36: 1-12, 1933.

  14. Chedid, A., Jao, W. Hereditary tumors of the carotid bodies and chronic obstructive pulmonary disease. Cancer 33: 1635-1641, 1974. [PubMed: 4366403, related citations] [Full Text]

  15. DeAngelis, L. M., Kelleher, M. B., Post, K. D., Fetell, M. R. Multiple paragangliomas in neurofibromatosis: a new neuroendocrine neoplasia. Neurology 37: 129-133, 1987. [PubMed: 2879257, related citations] [Full Text]

  16. Desai, M. G., Patel, C. C. Heredo-familial carotid body tumours. Clin. Radiol. 12: 214-217, 1961. [PubMed: 13722111, related citations] [Full Text]

  17. Devilee, P., Heutink, P., van der Mey, A. G. L., Oostra, B. A., van Ommen, G. J.-B., Cornelisse, C. J. Mapping the genomically imprinted gene responsible for hereditary paragangliomas on 11q. (Abstract) Am. J. Hum. Genet. 51 (suppl.): A61 only, 1992.

  18. Devilee, P., van Schothorst, E. M., Bardoel, A. F. J., Bonsing, B., Kuipers-Dijkshoorn, N., James, M. R., Fleuren, G., van der Mey, A. G. L., Cornelisse, C. J. Allelotype of head and neck paragangliomas: allelic imbalance is confined to the long arm of chromosome 11, the site of the predisposing locus PGL. Genes Chromosomes Cancer 11: 71-78, 1994. [PubMed: 7529551, related citations] [Full Text]

  19. Gimm, O., Armanios, M., Dziema, H., Neumann, H. P. H., Eng, C. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res. 60: 6822-6825, 2000. [PubMed: 11156372, related citations]

  20. Gruber, H., Metson, R. Carotid body paraganglioma regression with relief of hypoxemia. Ann. Intern. Med. 92: 800-802, 1980. [PubMed: 7387023, related citations] [Full Text]

  21. Grufferman, S., Gillman, M. W., Pasternak, L. R., Peterson, C. L., Young, W. G., Jr. Familial carotid body tumors: case report and epidemiologic review. Cancer 46: 2116-2122, 1980. [PubMed: 7000334, related citations] [Full Text]

  22. Guild, S. R. A hitherto unrecognized structure, the glomus jugularis in man. (Abstract) Anat. Rec. 79 (suppl. 2): 28 only, 1941.

  23. Guild, S. R. The glomus jugulare, a nonchromaffin paraganglion, in man. Ann. Otol. Rhinol. Laryng. 62: 1045-1071, 1953. [PubMed: 13114831, related citations] [Full Text]

  24. Heesterman, B. L., Bayley, J. P., Tops, C. M., Hes, F. J., van Brussel, B. T. J., Corssmit, E. P. M., Hamming, J. F., van der Mey, A. G. L., Jansen, J. C. High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Europ. J. Hum. Genet. 21: 469-470, 2013. [PubMed: 22948026, related citations] [Full Text]

  25. Hensen, E. F., Jansen, J. C., Siemers, M. D., Ossterwijk, J. C., Vriends, A. H. J. T., Corssmit, E. P. M., Bayley, J.-P., van der Mey, A. G. L., Cornelisse, C. J., Devilee, P. The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. Europ. J. Hum. Genet. 18: 62-66, 2010. [PubMed: 19584903, images, related citations] [Full Text]

  26. Hensen, E. F., van Duinen, N., Jansen, J. C., Corssmit, E. P. M., Tops, C. M. J., Romijn, J. A., Vriends, A. H. J. T., van der Mey, A. G. L., Cornelisse, C. J., Devilee, P., Bayley, J. P. High prevalence of founder mutations of the succinate dehydrogenase genes in the Netherlands. Clin. Genet. 81: 284-288, 2012. [PubMed: 21348866, related citations] [Full Text]

  27. Herrmann, J. Delayed mutation model: carotid body tumors and retinoblastoma. In: Mulvihill, J. J.; Miller, R. W.; Fraumeni, J. F., Jr.: Genetics of Human Cancer. New York: Raven Press (pub.) 1977. Pp. 417-438.

  28. Heutink, P., van der Mey, A. G. L., Sandkuijl, L. A., van Gils, A. P. G., Bardoel, A., Breedveld, G. J., van Vliet, M., van Ommen, G.-J. B., Cornelisse, C. J., Oostra, B. A., Weber, J. L., Devilee, P. A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to chromosome 11q23-qter. Hum. Molec. Genet. 1: 7-10, 1992. [PubMed: 1301144, related citations] [Full Text]

  29. Heutink, P., van Schothorst, E. M., van der Mey, A. G. L., Bardoel, A., Breedveld, G., Pertijs, J., Sandkuijl, L. A., van Ommen, G.-J. B., Cornelisse, C. J., Oostra, B. A., Devilee, P. Further localization of the gene for hereditary paragangliomas and evidence for linkage in unrelated families. Europ. J. Hum. Genet. 2: 148-158, 1994. [PubMed: 7834274, related citations] [Full Text]

  30. Karasov, R. S., Sheps, S. G., Carney, J. A., van Heerden, J. A., DeQuattro, V. Paragangliomatosis with numerous catecholamine-producing tumors. Mayo Clin. Proc. 57: 590-595, 1982. [PubMed: 6213823, related citations]

  31. Katz, A. D. Carotid body tumors in a large family group. Am. J. Surg. 108: 570-573, 1964. [PubMed: 14211450, related citations] [Full Text]

  32. Khafagi, F., Egerton-Vernon, J., van Doorn, T., Foster, W., McPhee, I. B., Allison, R. W. G. Localization and treatment of familial malignant nonfunctional paraganglioma with iodine-131 MIBG: report of two cases. J. Nucl. Med. 28: 528-531, 1987. [PubMed: 2437268, related citations]

  33. Knudson, A. G., Jr. Genetics of human cancer. Annu. Rev. Genet. 20: 231-251, 1986. [PubMed: 2880556, related citations] [Full Text]

  34. Kroll, A. J., Alexander, B., Cochios, F., Pechet, L. Hereditary deficiencies of clotting factors VII and X associated with carotid-body tumors. New Eng. J. Med. 270: 6-13, 1964. [PubMed: 14062129, related citations] [Full Text]

  35. Ladenheim, J. C., Sachs, E., Jr. Familial tumors of the 'glomus jugulare': report of 2 cases, with a note on the vascular origin of the glomera. Neurology 11: 303-309, 1961. [PubMed: 13758152, related citations] [Full Text]

  36. Lee, S. P., Nicholson, G. I., Hitchcock, G. C. Familial abdominal chemodectomas with associated cutaneous angiolipomas. Pathology 9: 173-177, 1977. [PubMed: 195258, related citations] [Full Text]

  37. Leube, B., Huber, R., Goecke, T. O., Sandmann, W., Royer-Pokora, B. SDHD mutation analysis in seven German patients with sporadic carotid body paraganglioma: one novel mutation, no Dutch founder mutation and further evidence that G12S is a polymorphism. (Letter) Clin. Genet. 65: 61-63, 2004. [PubMed: 15032977, related citations] [Full Text]

  38. Mariman, E. C. M., van Beersum, S. E. C., Cremers, C. W. R. J., Struycken, P. M., Ropers, H. H. Fine mapping of a putatively imprinted gene for familial non-chromaffin paragangliomas to chromosome 11q13.1: evidence for genetic heterogeneity. Hum. Genet. 95: 56-62, 1995. [PubMed: 7814027, related citations] [Full Text]

  39. Masuoka, J., Brandner, S., Paulus, W., Soffer, D., Vital, A., Chimelli, L., Jouvet, A., Yonekawa, Y., Kleihues, P., Ohgaki, H. Germline SDHD mutation in paraganglioma of the spinal cord. Oncogene 20: 5084-5086, 2001. [PubMed: 11526495, related citations] [Full Text]

  40. Mhatre, A. N., Li, Y., Feng, L., Gasperin, A., Lalwani, A. K. SDHB, SDHC, and SDHD mutation screen in sporadic and familial head and neck paragangliomas. Clin. Genet. 66: 461-466, 2004. [PubMed: 15479192, related citations] [Full Text]

  41. Milunsky, J., DeStefano, A. L., Huang, X.-L., Baldwin, C. T., Michels, V. V., Jako, G., Milunsky, A. Familial paragangliomas: linkage to chromosome 11q23 and clinical implications. Am. J. Med. Genet. 72: 66-70, 1997. [PubMed: 9295078, related citations] [Full Text]

  42. Milunsky, J. M., Maher, T. A., Michels, V. V., Milunsky, A. Novel mutations and the emergence of a common mutation in the SDHD gene causing familial paraganglioma. Am. J. Med. Genet. 100: 311-314, 2001. [PubMed: 11343322, related citations] [Full Text]

  43. Neumann, H. P. H., Pawlu, C., Peczkowska, M., Bausch, B., McWhinney, S. R., Muresan, M., Buchta, M., Franke, G., Klisch, J., Bley, T. A., Hoegerle, S., Boedeker, C. C., Opocher, G., Schipper, J., Januszewicz, A., Eng. C. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292: 943-951, 2004. Note: Erratum: JAMA 292: 1686 only, 2004. [PubMed: 15328326, related citations] [Full Text]

  44. Nissenblatt, M. J. Cyanotic heart disease: 'low altitude' risk for carotid body tumor? Johns Hopkins Med. J. 142: 18-22, 1978. [PubMed: 625092, related citations]

  45. Oosterwijk, J. C., Jansen, J. C., van Schothorst, E. M., Oosterhof, A. W., Devilee, P., Bakker, E., Zoeteweij, M. W., van der Mey, A. G. L. First experiences with genetic counselling based on predictive DNA diagnosis in hereditary glomus tumours (paragangliomas). J. Med. Genet. 33: 379-383, 1996. [PubMed: 8733047, related citations] [Full Text]

  46. Parkin, J. L. Familial multiple glomus tumors and pheochromocytomas. Ann. Otol. Rhinol. Laryng. 90: 60-63, 1981. [PubMed: 6258467, related citations] [Full Text]

  47. Parry, D. M., Li, F. P., Strong, L. C., Carney, J. A., Schottenfeld, D., Reimer, R. R., Grufferman, S. Carotid body tumors in humans: genetics and epidemiology. J. Nat. Cancer Inst. 68: 573-578, 1982. [PubMed: 6951072, related citations]

  48. Pigny, P., Vincent, A., Bauters, C. C., Bertrand, M., de Montpreville, V. T., Crepin, M., Porchet, N., Caron, P. Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation. J. Clin. Endocr. Metab. 93: 1609-1615, 2008. [PubMed: 18211978, related citations] [Full Text]

  49. Pratt, L. W. Familial carotid body tumors. Arch. Otolaryng. 97: 334-336, 1973. [PubMed: 4699542, related citations] [Full Text]

  50. Prontera, P., Ferrando, B., Giuliani, V., Falcinelli, F., Mencarelli, A., Rogaia, D., Pasini, B, Donti, E. A novel mutation in the SDHD gene responsible for familial paraganglioma. Medical and psychological implications. Genet. Counsel. 19: 413-418, 2008. [PubMed: 19239085, related citations]

  51. Resler, D. R., Snow, J. B., Williams, G. R. Multiplicity and familial incidence of carotid body and glomus jugulare tumors. Ann. Otol. Rhinol. Laryng. 75: 114-122, 1966. [PubMed: 4286420, related citations] [Full Text]

  52. Rosen, S. Glomus jugulare tumor of the middle ear with normal drum, improved biopsy technique. Ann. Otol. Rhinol. Laryng. 61: 448-451, 1952. [PubMed: 14944141, related citations] [Full Text]

  53. Strauchen, J. A. Germ-line mutations in nonsyndromic pheochromocytoma. (Letter) New Eng. J. Med. 347: 854-855, 2002. [PubMed: 12226162, related citations] [Full Text]

  54. van Baars, F., Cremers, C., van den Broek, P., Geerts, S., Veldman, J. Genetic aspects of nonchromaffin paraganglioma. Hum. Genet. 60: 305-309, 1982. [PubMed: 6286462, related citations] [Full Text]

  55. van der Mey, A. G., Maaswinkel-Mooy, P. D., Cornelisse, C. J., Schmidt, P. H., van de Kamp, J. J. Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet 334: 1291-1294, 1989. Note: Originally Volume II. [PubMed: 2574254, related citations] [Full Text]

  56. van Schothorst, E. M., Beekman, M., Torremans, P., Kuipers-Dijkshoorn, N. J., Wessels, H. W., Bardoel, A. F. J., van der Mey, A. G. L., van der Vijver, M. J., van Ommen, G.-J. B., Devilee, P., Cornelisse, C. J. Paragangliomas of the head and neck region show complete loss of heterozygosity at 11q22-q23 in chief cells and the flow-sorted DNA aneuploid fraction. Hum. Path. 29: 1045-1049, 1998. [PubMed: 9781639, related citations] [Full Text]

  57. van Schothorst, E. M., Jansen, J. C., Grooters, E., Prins, D. E. M., Wiersinga, J. J., van der Mey, A. G. L., van Ommen, G.-J. B., Devilee, P., Cornelisse, C. J. Founder effect at PGL1 in hereditary head and neck paraganglioma families from The Netherlands. Am. J. Hum. Genet. 63: 468-473, 1998. [PubMed: 9683583, related citations] [Full Text]

  58. Wilson, H. Carotid body tumors: familial and bilateral. Ann. Surg. 171: 843-848, 1970. [PubMed: 5420930, related citations] [Full Text]


Cassandra L. Kniffin - updated : 5/8/2013
Cassandra L. Kniffin - updated : 4/11/2012
Cassandra L. Kniffin - updated : 5/14/2010
Cassandra L. Kniffin - updated : 3/9/2010
Ada Hamosh - updated : 9/15/2009
John A. Phillips, III - updated : 2/26/2009
Cassandra L. Kniffin - updated : 1/5/2009
John A. Phillips, III - updated : 4/9/2007
Victor A. McKusick - updated : 4/28/2005
Cassandra L. Kniffin - reorganized : 1/31/2005
Cassandra L. Kniffin - updated : 1/19/2005
Victor A. McKusick - updated : 8/13/2003
Michael B. Petersen - updated : 6/23/2003
Victor A. McKusick - updated : 9/30/2002
Victor A. McKusick - updated : 2/6/2002
Victor A. McKusick - updated : 12/10/2001
Sonja A. Rasmussen - updated : 6/13/2001
Ada Hamosh - updated : 2/2/2000
Victor A. McKusick - updated : 1/10/2000
Victor A. McKusick - updated : 4/26/1999
Victor A. McKusick - updated : 1/20/1999
Victor A. McKusick - updated : 7/16/1998
Victor A. McKusick - updated : 10/3/1997
Moyra Smith - updated : 1/27/1997
Creation Date:
Victor A. McKusick : 6/2/1986
carol : 10/17/2023
ckniffin : 10/11/2023
carol : 04/21/2023
alopez : 06/24/2019
alopez : 06/21/2019
ckniffin : 06/14/2019
carol : 08/23/2016
carol : 05/23/2016
carol : 5/20/2013
ckniffin : 5/8/2013
alopez : 4/13/2012
alopez : 4/13/2012
terry : 4/11/2012
ckniffin : 4/11/2012
wwang : 8/16/2011
ckniffin : 8/15/2011
wwang : 5/24/2010
ckniffin : 5/14/2010
wwang : 4/7/2010
ckniffin : 3/9/2010
alopez : 9/17/2009
terry : 9/15/2009
alopez : 2/26/2009
terry : 2/6/2009
wwang : 2/5/2009
ckniffin : 1/5/2009
carol : 4/9/2007
carol : 5/1/2006
tkritzer : 5/12/2005
terry : 4/28/2005
carol : 1/31/2005
ckniffin : 1/19/2005
ckniffin : 3/23/2004
carol : 3/9/2004
tkritzer : 2/27/2004
cwells : 11/6/2003
tkritzer : 8/18/2003
terry : 8/13/2003
cwells : 6/23/2003
mgross : 10/1/2002
carol : 9/30/2002
ckniffin : 5/15/2002
alopez : 2/6/2002
carol : 12/10/2001
mcapotos : 6/13/2001
mcapotos : 6/13/2001
alopez : 10/31/2000
alopez : 2/3/2000
terry : 2/2/2000
mgross : 1/10/2000
carol : 11/8/1999
mgross : 5/12/1999
terry : 5/5/1999
mgross : 4/28/1999
terry : 4/26/1999
carol : 1/29/1999
terry : 1/20/1999
carol : 12/15/1998
terry : 8/5/1998
terry : 7/16/1998
jenny : 10/7/1997
terry : 10/3/1997
mark : 2/12/1997
mark : 2/12/1997
terry : 2/5/1997
terry : 1/27/1997
mark : 1/24/1997
mark : 7/9/1996
terry : 6/28/1996
terry : 3/3/1995
carol : 2/6/1995
mimadm : 1/14/1995
pfoster : 4/27/1994
warfield : 4/12/1994
carol : 7/12/1993

# 168000

PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 1; PPGL1


Alternative titles; symbols

PARAGANGLIOMAS 1; PGL1
PARAGANGLIOMAS, FAMILIAL, 1
PARAGANGLIOMATA; PGL
GLOMUS TUMORS, FAMILIAL, 1
CHEMODECTOMAS
CAROTID BODY TUMORS; CBT1
GLOMUS JUGULARE TUMORS
PARAGANGLIOMA, CAROTID BODY
PARAGANGLIOMAS, FAMILIAL NONCHROMAFFIN, 1


SNOMEDCT: 127028003, 127030001, 302834008, 30699005, 32037004, 51747000;   ORPHA: 29072;   DO: 0050773;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
11q23.1 Pheochromocytoma/paraganglioma syndrome 1 168000 Autosomal dominant 3 SDHD 602690

TEXT

A number sign (#) is used with this entry because of evidence that pheochromocytoma/paraganglioma syndrome-1 (PPGL1) is caused by heterozygous mutation in the SDHD gene (602690), which encodes the small subunit of cytochrome B in succinate-ubiquinone oxidoreductase, on chromosome 11q23.


Description

Pheochromocytoma/paraganglioma syndrome-1 (PPGL1) is an autosomal dominant disorder characterized by the development of neuroendocrine tumors, usually in adulthood. Pheochromocytomas arise from chromaffin cells in the adrenal medulla, whereas paragangliomas arise in extra-adrenal sympathetic ganglia in the thorax, abdomen, and pelvis or from parasympathetic paraganglia in the head and neck area (summary by Cascon et al., 2023).

Paragangliomas, also referred to as 'glomus body tumors,' are tumors derived from paraganglia located throughout the body. Nonchromaffin types primarily serve as chemoreceptors (hence, the tumor name 'chemodectomas') and are located in the head and neck region (i.e., carotid body, jugular, vagal, and tympanic regions), whereas chromaffin types have endocrine activity, conventionally referred to as 'pheochromocytomas,' and are usually located below the head and neck (i.e., adrenal medulla and pre- and paravertebral thoracoabdominal regions). PPGL can manifest as nonchromaffin head and neck tumors only, adrenal and/or extraadrenal pheochromocytomas only, or a combination of the 2 types of tumors (Baysal, 2002; Neumann et al., 2004).

The triad of gastric leiomyosarcoma, pulmonary chondroma, and extraadrenal paraganglioma constitutes a syndrome that occurs mainly in young women and is known as the Carney triad (604287). This triad is not to be confused with the other Carney syndrome of myxoma, spotty pigmentation, and endocrinopathy (160980).

Baysal (2008) provided a review of the molecular pathogenesis of hereditary paraganglioma.

Genetic Heterogeneity of Pheochromocytoma/Paraganglioma Syndrome

See also PPGL2 (601650), caused by mutation in the SDHAF2 gene (613019) on chromosome 11q13; PPGL3 (605373), caused by mutation in the SDHC gene (602413) on chromosome 1q21; PPGL4 (115310), caused by mutation in the SDHB gene (185470) on chromosome 1p36; PPGL5 (614165), caused by mutation in the SDHA gene (600857) on chromosome 5p15; PPGL6 (618464), caused by mutation in the SLC25A11 gene (604165) on chromosome 17p13; and PPGL7 (618475), caused by mutation in the DLST gene (126063) on chromosome 14q24.


Clinical Features

Kroll et al. (1964) found carotid body tumors in 12 members of a family in an autosomal dominant pattern of inheritance. Resler et al. (1966) reported a patient with bilateral carotid body tumors and a glomus jugulare tumor. The authors noted that familial carotid body tumors tended to be multiple. Familial glomus jugulare tumors were likely described in 3 affected sisters reported in 1937 by Goekoop (cited by Rosen, 1952). Also see Ladenheim and Sachs (1961). Bartels (1949) identified carotid body tumors in members of 3 successive generations of a family.

Wilson (1970) reviewed familial reports of carotid body tumors and described a family with male-to-male transmission and a skipped generation. Pratt (1973) reviewed the literature and reported 8 new cases of either unilateral or bilateral carotid body tumors in 4 generations of a kindred. In 1 generation of this family, 4 sisters had bilateral tumors and 1 brother had unilateral tumors. None of the 8 tumors reported were malignant. Chedid and Jao (1974) identified carotid body tumors in 6 members of 2 consecutive generations of a family. Four also had chronic obstructive pulmonary disease with persistently high arterial pCO(2) and low pO(2). The authors theorized that the tumors started as hyperplasia secondary to the stimulus of these altered blood gases. Nissenblatt (1978) reported a young woman with hypoplastic right heart syndrome who developed a carotid body tumor at age 28 years. He suggested a connection between low-oxygen situations such as high altitude living, emphysema, and cyanotic congenital heart disease, and the development of carotid body tumors.

Grufferman et al. (1980) reported 2 sisters with carotid body tumors and reviewed reports of 88 familial and 835 nonfamilial CBT cases. Familial cases had an equal sex ratio and followed autosomal dominant inheritance. Bilateral disease occurred in 31.8% of familial cases and 4.4% of sporadic cases. Six percent of all patients developed second primary tumors, mostly other paragangliomas. Parry et al. (1982) reviewed the records of 222 histologically diagnosed cases of carotid body tumors, including 146 females and 76 males. The mean age at tumor development was 44.7 years. In 16 patients who had other extraadrenal paragangliomas, suggesting a multiple primary tumor syndrome, the diagnosis occurred earlier (mean, 35.4 years; p less than 0.01). Five patients also developed thyroid cancer. Familial cases were more often bilateral and diagnosed slightly earlier.

Van Baars et al. (1982) provided a review of the literature of familial nonchromaffin paragangliomas. Carotid body tumors were the most common, followed by glomus jugulare, glomus vagale, and glomus tympanicum.

Parkin (1981) reported 2 unrelated families with a hereditary syndrome of pheochromocytoma associated with multiple glomus tumors of the head and neck. DeAngelis et al. (1987) reported the occurrence of pheochromocytoma and multiple paragangliomas in a patient with neurofibromatosis (162200). Karasov et al. (1982) described a sporadic case of a girl with a record number of 21 paragangliomas removed between the ages of 13 and 17 years, with evidence of remaining tumors. The tumors were catecholamine-producing. Khafagi et al. (1987) reported 2 unrelated adults, both of whom had a positive family history of paraganglioma. Both had malignant nonfunctional paragangliomas detected by uptake of iodine-131 metaiodobenzylguanidine; this agent proved to be of therapeutic value in the management of unresectable metastases.

Van Schothorst et al. (1998) reported 10 families with head and neck paragangliomas who originated from the same geographic region in the Netherlands. The carotid bifurcation was the most frequently affected site (57% of all head and neck tumors), and multiple paragangliomas occurred in 66% of patients. Three patients from different families developed a pheochromocytoma. No affected offspring of female carriers was observed, and all affected family members received the disease gene from their father.

Prontera et al. (2008) reported an Italian family with PGL1. The proband was a 49-year-old man who presented with throat pain, dysphonia, dyspnea, and mild hypertension, and was found to have bilateral carotid chemodectomas with multiple highly vascularized laryngeal and carotid paragangliomas. Family history revealed that the father, who died at age 71 of lung cancer, was diagnosed at age 66 with bilateral paragangliomas in the pericarotid region. The 55-year-old sister of the proband developed multiple laryngeal and carotid paragangliomas at age 52. The proband and his sister both carried a heterozygous truncating mutation in the SDHD gene.

Hensen et al. (2010) used the Kaplan-Meier method to calculate the age-specific penetrance of paragangliomas in 243 members of a large 7-generation Dutch family (Oosterwijk et al., 1996) with PGL1 caused by a founder mutation in the SDHD gene (D92Y; 602690.0004). The age at onset of symptoms ranged from 14 to 47 years. By clinical signs and symptoms alone, the penetrance reached a maximum of 57% by age 47 years. When MRI detection of occult paragangliomas was included, penetrance was estimated at 54% by age 40, 68% by age 60, and 87% by age 70. Multiple tumors were found in 65%, and 8% of paraganglioma patients had pheochromocytomas. One (3%) patient developed a malignant paraganglioma. None of 11 instances of maternal transmission of the mutation resulted in the development of paragangliomas. The findings indicated that the majority of mutation carriers will eventually develop head and neck paragangliomas, although Hensen et al. (2010) stated that the penetrance in this study was lower than some previous estimates. Hensen et al. (2010) emphasized the importance of including clinically unaffected mutation carriers in estimates of penetrance.

Among 47 asymptomatic carriers of SDHD mutations screened by physical examination or MRI, Heesterman et al. (2013) found that 28 (59.6%) carried a total of 57 tumors, including 38 carotid body tumors, 17 vagal body tumors, and 2 jugulotympanic tumors. Multiple tumors were seen in 34% of patients. Two patients (4.3%) had a sympathetic paraganglioma. The report indicated that a high percentage of asymptomatic SDHD mutation carriers have occult head and neck paragangliomas.


Inheritance

Maternal Imprinting

From a study of 15 pedigrees, van der Mey et al. (1989) concluded that familial paragangliomas, which they referred to as hereditary glomus tumors, were inherited almost exclusively through the paternal line, a finding inconsistent with simple autosomal dominant transmission. They suggested a role for genomic imprinting, in which the maternally derived gene is inactivated during female oogenesis and can be reactivated only during spermatogenesis. Heutink et al. (1992) stated that all individuals with hereditary paragangliomas had inherited the disease gene from their father; expression of the phenotype was not observed in the offspring of an affected female until subsequent transmission of the gene through a male carrier. The observations strongly suggested genomic imprinting.

Baysal et al. (1997) noted that the age of onset of symptoms was significantly different between fathers and children: affected children had an earlier age of onset in 39 of 57 father-child pairs.

Maternal Inheritance

Pigny et al. (2008) reported what they believed to be the first description of a paraganglioma kindred with maternal transmission of the mutated SDHD (602690) allele. A boy received the W43X mutation (602690.0023) from his mother and developed a glomus tympanicum paraganglioma at 11 years of age. He shared only the 11q23 haplotype with the other affected members of the family. Pigny et al. (2008) concluded that maternal transmission of a SDHD-linked paraganglioma, even if a rare event, can occur.


Mapping

In a large Dutch pedigree with hereditary paragangliomas, Heutink et al. (1992) found linkage with marker D11S147 located at chromosome 11q23-qter (maximum lod score of 6.0 at theta = 0.0 ). Likelihood calculations yielded a very high odds ratio in favor of genomic imprinting versus absence of genomic imprinting. Devilee et al. (1992) performed haplotyping in this large Dutch family using 15 markers in the region 11q13-q23. Two recombination events placed the PGL locus distal to STMY (185260) and proximal to D11S836, thus excluding the oncogenes INT2 (164950) and ETS1 (164720) as the site of the mutation. In an affected PGL family that showed imprinting, Mariman et al. (1995) found linkage to the locus on distal 11q.

In patients with familial nonchromaffin paragangliomas, Devilee et al. (1994) found loss of heterozygosity (LOH) only on chromosome 11, with a marked clustering on the distal half of the long arm. In all 8 cases in which they could determine the parental origin, the allele undergoing loss was maternally derived. However, LOH in all tumors was only partial, and it was not clear whether this represented an allelic imbalance or cellular heterogeneity. In a later study, van Schothorst et al. (1998) performed LOH analysis for the 11q22-q23 region on DNA-aneuploid tumor cells, enriched by flow sorting, and on purified chief cell fractions obtained by single-cell microdissection. Complete LOH was found in both types of cells, indicating that the chief cells were clonal proliferated tumor cells.

Oosterwijk et al. (1996) gave the location of the PGL1 gene as 11q22.3-q23. They offered genetic counseling on the basis of DNA linkage diagnosis in an extended Dutch pedigree. Presymptomatic testing of the paternal allele was performed in 16 cases; 4 of these appeared to have the at-risk haplotype and in 2 of the 4 a glomus tumor was subsequently detected on MRI. In 1 case linkage results were inconclusive because of recombination and 1 person did not want to learn his test result. The maternal allele was tested for carrier status in 4 cases of which 1 appeared to be a carrier.

Baysal et al. (1997) reported linkage of paraganglioma to chromosome 11q23 in 3 of 6 North American families. Recombinants narrowed the critical region to a 4.5-Mb interval flanked by the markers D11S1647 and D11S622. Partial allelic loss of strictly maternal origin was detected in 5 of 19 tumors. Milunsky et al. (1997) confirmed linkage to 11q23 in studies of 3 affected families. The inheritance pattern was consistent with genetic imprinting; the disorder was transmitted only by males.

Another 10 families with hereditary head and neck paragangliomas were ascertained by van Schothorst et al. (1998) from the same geographic region as that from which the large PGL1-linked Dutch family originated (Heutink et al., 1992). They determined the disease-linked haplotype, as defined by 13 markers encompassing a large interval on 11q21-q23, in these families and showed that alleles were identical for 6 contiguous markers spanning a genetic distance of 6 cM and containing PGL1. Despite this strong indication of a common ancestor, no kinship between the families could be demonstrated through genealogic surveys going back to 1800. Baysal et al. (1999) reevaluated the haplotype data of the multigenerational Dutch PGL1-linked family, using 2 additional single tandem repeat polymorphisms (STRPs) contained within the PGL1 critical interval proposed by van Schothorst et al. (1998). They excluded this interval, and instead predicted a nonoverlapping, more proximal 2-Mb critical interval between markers D11S1647 and D11S897. Analysis of 4 new American PGL families defined the telomeric border of the critical region as D11S1347. Among 3 unrelated American PGL families, significant haplotype sharing within this new interval was observed, strongly suggesting that they originated from a common ancestor. In sum, the authors refined the PGL1 locus to a 1.5-Mb region between D11S1986 and D11S1347.


Molecular Genetics

Astrom et al. (2003) stated that a large number of PGL1 families had been reported from the Netherlands and that there may be Dutch founder mutations.

In affected members of families with hereditary paraganglioma, Baysal et al. (2000) identified mutations in the SDHD gene (602690.0001-602690.0005), including the Dutch founder mutation (D92Y; 602690.0004).

Gimm et al. (2000) identified several mutations in the SDHD gene in unrelated patients. One patient had a pheochromocytoma and a carotid body paraganglioma (see 602690.0010); 2 unrelated patients, 1 with an extraadrenal intraabdominal pheochromocytoma with involvement of the jugular fossa, suggesting malignancy, and 1 with an isolated intestinal lipoma, had the same mutation (602690.0011); and a 33-year-old woman had 2 extraadrenal pheochromocytomas, 1 intraabdominal and 1 intrathoracic (see 602690.0002). Finally, the authors identified a somatic SDHD mutation in a pheochromocytoma (602690.0003).

In 7 families with familial paragangliomas, Milunsky et al. (2001) identified mutations in the SDHD gene (602690.0006-602690.0009). Three unrelated families had the same mutation (602690.0003), suggesting a founder effect. A restriction enzyme assay was developed for initial screening for the common mutation.

Cascon et al. (2002) performed mutation analysis of the SDHD gene in 25 consecutive, unrelated patients with pheochromocytoma and/or paraganglioma, with or without family history. There were 18 patients with pheochromocytoma, 4 with paraganglioma alone, and 3 with both, who had tested negative for germline mutations in the VHL (608537) and RET (164761) genes. Two novel truncating mutations were detected, a 4-bp deletion (602690.0022) in an apparently sporadic case of paraganglioma and pheochromocytoma, and a nonsense mutation (602690.0023) in a patient with paraganglioma with a family history of pheochromocytoma.

In a patient of German descent with sporadic bilateral carotid body paragangliomata, Leube et al. (2004) identified a frameshift mutation in the SDHD gene (602690.0020).

Mhatre et al. (2004) performed a mutation screen of the SDHB, SDHC, and SDHD genes in blood and tumor samples of 14 sporadic and 3 familial cases of head and neck paragangliomas. Germline mutations in SDHB and SDHD were identified in 2 of the 3 affected individuals with familial PGL, whereas no germline or somatic mutations were identified in the 14 sporadic cases. The presence of mutations within SDHB and SDHD in 2 of the 3 samples of familial PGL and absence of mutations in sporadic cases is consistent with a significant contribution of these genes to familial but not sporadic PGL.


Heterogeneity

Carotid Body Paragangliomas with Sensorineural Hearing Loss

Badenhop et al. (2001) studied 4 families with familial carotid body paragangliomas, 2 of which exhibited coinheritance of paragangliomas and sensorineural hearing loss or tinnitus. Sequence analysis identified mutations in exon 1 and exon 3 of the SDHD gene, including a novel 2-bp deletion in exon 3 creating a premature stop codon at position 67 (602690.0013); a novel 3-bp deletion in exon 3 resulting in the loss of tyr93 (602690.0014); a missense mutation in exon 3 resulting in a pro81-to-leu substitution (602690.0003); and a novel G-to-C substitution in exon 1 resulting in a met1-to-val substitution (602690.0015). The PGL1 region contains another gene, DPP2/TIMM8B (606659), a homolog of the X-linked TIMM8A gene (300356), mutations in which cause dystonia and deafness seen in Mohr-Tranebjaerg syndrome (304700). The authors found no base changes in the TIMM8B gene; thus, it would seem that the association of paraganglioma with sensorineural hearing loss cannot be explained by the proximity of the TIMM8B and SDHD genes.


Genotype/Phenotype Correlations

In a review of several studies, Baysal et al. (2002) found that 83 cases of paragangliomas-1 in 'unrelated' families and patients were attributable to 3 founder populations in the Netherlands, in stark contrast to 25 distinct SDHD mutations reported among 43 independent familial and nonfamilial cases in other parts of the world. Astrom et al. (2003) interpreted this finding as suggesting that low altitudes in the Netherlands reduce penetrance and relax the natural selection on SDHD mutations. They studied the influence of altitude on the phenotype of PGL1 in 58 patients from 23 families. Patients who were diagnosed with single tumors at their first clinical evaluation lived at lower average altitudes and were exposed to lower altitude-years than those with multiple tumors (p less than 0.012). Nonsense/splicing mutation carriers developed symptoms 8.5 years earlier than missense mutation carriers (p less than 0.012). Pheochromocytomas developed in 6 patients, 5 of whom had nonsense mutations. Patients with pheochromocytomas also lived at higher average altitudes and were exposed to higher altitude-years than those without them. Astrom et al. (2003) concluded that collectively, these data suggested that higher altitudes and nonsense/splicing mutations are associated with increased severity in PGL1 and supported the hypothesis that SDHD mutations impair oxygen sensing.

In a population-based genetic study of 334 unrelated patients with adrenal or extraadrenal pheochromocytomas and 83 patients with head and neck paragangliomas, Neumann et al. (2004) found that 12% of patients had a mutation in either the SDHB or SDHD gene, with equal distribution between the 2 genes (25 and 24 patients with mutations in the SDHB and SDHD genes, respectively). Mean age at diagnosis was similar between the 2 groups (approximately 30 years). Inheritance of SDHD mutations was consistent with maternal imprinting. Examination of relatives yielded a total of 32 and 34 manifesting carriers of SDHB and SDHD mutations, respectively. Multiple tumors occurred in 28% of SDHB carriers and 74% of SDHD carriers; adrenal pheochromocytomas occurred in 28% of SDHB carriers and 53% of SDHD carriers, whereas extraadrenal pheochromocytomas were identified in 48% of SDHB carriers and 21% of SDHD carriers; head and neck paragangliomas occurred in 31% of SDHB carriers and 79% of SDHD carriers; and malignancy occurred in 34% of SDHB carriers but no SDHD carriers. Two related SDHB carriers had renal cell carcinoma, and 1 SDHB and 1 SDHD carrier each had papillary thyroid carcinoma. Age-related penetrance for carriers of the 2 mutations was similar: SDHB and SDHD carriers showed 77% and 86% penetrance by age 50 years, respectively.

Benn et al. (2006) determined genotype/phenotype associations in a cohort of patients with pheochromocytoma/paraganglioma syndromes and SDHB or SDHD mutations. SDHB mutation carriers were more likely than SDHD mutation carriers to develop extraadrenal pheochromocytomas and malignant disease, whereas SDHD mutation carriers had a greater propensity to develop head and neck paragangliomas and multiple tumors. For the index cases, there was no difference between 43 SDHB and 19 SDHD mutation carriers in the time to first diagnosis (34 vs 28 years, respectively; p = 0.3). However, when all 112 mutation carriers were included, the estimated age-related penetrance was different for SDHB versus SDHD mutation carriers (p = 0.008).


Population Genetics

Hensen et al. (2012) determined the mutation frequency of 4 succinate dehydrogenase genes in a total of 1,045 patients from 340 Dutch families with paraganglioma and pheochromocytoma. Mutations were identified in 690 cases from 239 families. The most commonly affected gene in mutation carriers was SDHD (87.1%), followed by SDHAF2 (6.7%), SDHB (5.9%), and SDHC (0.3%). Almost 70% of all carriers had the founder mutation D92Y (602690.0004) in SDHD; approximately 89% of all SDH mutation carriers had 1 of 6 Dutch founder mutations. The dominance of SDHD mutations was unique to the Netherlands, contrasting with the higher prevalence of SDHB mutations found elsewhere.


Nomenclature

Strauchen (2002) noted that the interchangeable use of 'paraganglioma' and 'glomus tumor' was a 'common point of confusion.' He emphasized that the glomus tumor is a tumor of modified perivascular smooth muscle, which frequently presents as a painful subungual mass, and is unrelated to tumors of the adrenal and extraadrenal paraganglia. Jugulotympanic paraganglioma is often referred to as a 'glomus jugulare tumor.' This tumor arises from minute, anatomically dispersed paraganglia located at the base of the skull and temporal bone and is closely related to similar tumors of the carotid body and other extraadrenal paraganglia. It is unrelated to the much more common glomus tumor of skin and soft tissue. See 138000 for an inherited form of smooth muscle tissue glomus tumors.


History

The glomus jugulare was first discovered by Stacy R. Guild at Johns Hopkins in 1941 (Guild (1941, 1953)).


See Also:

Chase (1933); Desai and Patel (1961); Gruber and Metson (1980); Herrmann (1977); Heutink et al. (1994); Katz (1964); Knudson (1986); Lee et al. (1977); Masuoka et al. (2001)

REFERENCES

  1. Astrom, K., Cohen, J. E., Willett-Brozick, J. E., Aston, C. E., Baysal, B. E. Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum. Genet. 113: 228-237, 2003. [PubMed: 12811540] [Full Text: https://doi.org/10.1007/s00439-003-0969-6]

  2. Badenhop, R. F., Cherian, S., Lord, R. S. A., Baysal, B. E., Taschner, P. E. M., Schofield, P. R. Novel mutations in the SDHD gene in pedigrees with familial carotid body paraganglioma and sensorineural hearing loss. Genes Chromosomes Cancer 31: 255-263, 2001. [PubMed: 11391796] [Full Text: https://doi.org/10.1002/gcc.1142]

  3. Bartels, J. De tumoren van het glomus jugulare. Thesis: Groningen (pub.) 1949.

  4. Baysal, B. E., Farr, J. E., Rubinstein, W. S., Galus, R. A., Johnson, K. A., Aston, C. E., Myers, E. N., Johnson, J. T., Carrau, R., Kirkpatrick, S. J., Myssiorek, D., Singh, D., Saha, S., Gollin, S. M., Evans, G. A., James, M. R., Richard, C. W., III. Fine mapping of an imprinted gene for familial nonchromaffin paragangliomas, on chromosome 11q23. Am. J. Hum. Genet. 60: 121-132, 1997. [PubMed: 8981955]

  5. Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., van der May, A., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., Richard, C. W., III, Cornelisse, C. J., Devilee, P., Devlin, B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287: 848-851, 2000. [PubMed: 10657297] [Full Text: https://doi.org/10.1126/science.287.5454.848]

  6. Baysal, B. E., van Schothorst, E. M., Farr, J. E., Grashof, P., Myssiorek, D., Rubinstein, W. S., Taschner, P., Cornelisse, C. J., Devlin, B., Devilee, P., Richard, C. W., III. Repositioning the hereditary paraganglioma critical region on chromosome band 11q23. Hum. Genet. 104: 219-225, 1999. [PubMed: 10323245] [Full Text: https://doi.org/10.1007/s004390050939]

  7. Baysal, B. E., Willett-Brozick, J. E., Lawrence, E. C., Drovdlic, C. M., Savul, S. A., McLeod, D. R., Yee, H. A., Brackmann, D. E., Slattery, W. H., III, Myers, E. N., Ferrell, R. E., Rubinstein, W. S. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J. Med. Genet. 39: 178-183, 2002. [PubMed: 11897817] [Full Text: https://doi.org/10.1136/jmg.39.3.178]

  8. Baysal, B. E. Hereditary paraganglioma targets diverse paraganglia. J. Med. Genet. 39: 617-622, 2002. [PubMed: 12205103] [Full Text: https://doi.org/10.1136/jmg.39.9.617]

  9. Baysal, B. E. Clinical and molecular progress in hereditary paraganglioma. J. Med. Genet. 45: 689-694, 2008. [PubMed: 18978332] [Full Text: https://doi.org/10.1136/jmg.2008.058560]

  10. Benn, D. E., Gimenez-Roqueplo, A.-P., Reilly, J. R., Bertherat, J., Burgess, J., Byth, K., Croxson, M., Dahia, P. L. M., Elston, M., Gimm, O., Henley, D., Herman, P., and 9 others. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocr. Metab. 91: 827-836, 2006. [PubMed: 16317055] [Full Text: https://doi.org/10.1210/jc.2005-1862]

  11. Cascon, A., Calsina, B., Monteagudo, M., Mellid, S., Diaz-Talavera, A., Curras-Freixes, M., Robledo, M. Genetic bases of pheochromocytoma and paraganglioma. J. Molec. Endocr. 70: e220167, 2023. [PubMed: 36520714] [Full Text: https://doi.org/10.1530/JME-22-0167]

  12. Cascon, A., Ruiz-Llorente, S., Cebrian, A., Telleria, D., Rivero, J. C., Diez, J. J., Lopez-Ibarra, P., Jaunsolo, M. A., Benitez, J., Robledo, M. Identification of novel SDHD mutations in patients with phaeochromocytoma and/or paraganglioma. Europ. J. Hum. Genet. 10: 457-461, 2002. [PubMed: 12111639] [Full Text: https://doi.org/10.1038/sj.ejhg.5200829]

  13. Chase, W. H. Familial and bilateral tumours of the carotid body. J. Path. Bact. 36: 1-12, 1933.

  14. Chedid, A., Jao, W. Hereditary tumors of the carotid bodies and chronic obstructive pulmonary disease. Cancer 33: 1635-1641, 1974. [PubMed: 4366403] [Full Text: https://doi.org/10.1002/1097-0142(197406)33:6<1635::aid-cncr2820330625>3.0.co;2-j]

  15. DeAngelis, L. M., Kelleher, M. B., Post, K. D., Fetell, M. R. Multiple paragangliomas in neurofibromatosis: a new neuroendocrine neoplasia. Neurology 37: 129-133, 1987. [PubMed: 2879257] [Full Text: https://doi.org/10.1212/wnl.37.1.129]

  16. Desai, M. G., Patel, C. C. Heredo-familial carotid body tumours. Clin. Radiol. 12: 214-217, 1961. [PubMed: 13722111] [Full Text: https://doi.org/10.1016/s0009-9260(61)80012-3]

  17. Devilee, P., Heutink, P., van der Mey, A. G. L., Oostra, B. A., van Ommen, G. J.-B., Cornelisse, C. J. Mapping the genomically imprinted gene responsible for hereditary paragangliomas on 11q. (Abstract) Am. J. Hum. Genet. 51 (suppl.): A61 only, 1992.

  18. Devilee, P., van Schothorst, E. M., Bardoel, A. F. J., Bonsing, B., Kuipers-Dijkshoorn, N., James, M. R., Fleuren, G., van der Mey, A. G. L., Cornelisse, C. J. Allelotype of head and neck paragangliomas: allelic imbalance is confined to the long arm of chromosome 11, the site of the predisposing locus PGL. Genes Chromosomes Cancer 11: 71-78, 1994. [PubMed: 7529551] [Full Text: https://doi.org/10.1002/gcc.2870110202]

  19. Gimm, O., Armanios, M., Dziema, H., Neumann, H. P. H., Eng, C. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res. 60: 6822-6825, 2000. [PubMed: 11156372]

  20. Gruber, H., Metson, R. Carotid body paraganglioma regression with relief of hypoxemia. Ann. Intern. Med. 92: 800-802, 1980. [PubMed: 7387023] [Full Text: https://doi.org/10.7326/0003-4819-92-6-800]

  21. Grufferman, S., Gillman, M. W., Pasternak, L. R., Peterson, C. L., Young, W. G., Jr. Familial carotid body tumors: case report and epidemiologic review. Cancer 46: 2116-2122, 1980. [PubMed: 7000334] [Full Text: https://doi.org/10.1002/1097-0142(19801101)46:9<2116::aid-cncr2820460934>3.0.co;2-s]

  22. Guild, S. R. A hitherto unrecognized structure, the glomus jugularis in man. (Abstract) Anat. Rec. 79 (suppl. 2): 28 only, 1941.

  23. Guild, S. R. The glomus jugulare, a nonchromaffin paraganglion, in man. Ann. Otol. Rhinol. Laryng. 62: 1045-1071, 1953. [PubMed: 13114831] [Full Text: https://doi.org/10.1177/000348945306200411]

  24. Heesterman, B. L., Bayley, J. P., Tops, C. M., Hes, F. J., van Brussel, B. T. J., Corssmit, E. P. M., Hamming, J. F., van der Mey, A. G. L., Jansen, J. C. High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Europ. J. Hum. Genet. 21: 469-470, 2013. [PubMed: 22948026] [Full Text: https://doi.org/10.1038/ejhg.2012.203]

  25. Hensen, E. F., Jansen, J. C., Siemers, M. D., Ossterwijk, J. C., Vriends, A. H. J. T., Corssmit, E. P. M., Bayley, J.-P., van der Mey, A. G. L., Cornelisse, C. J., Devilee, P. The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. Europ. J. Hum. Genet. 18: 62-66, 2010. [PubMed: 19584903] [Full Text: https://doi.org/10.1038/ejhg.2009.112]

  26. Hensen, E. F., van Duinen, N., Jansen, J. C., Corssmit, E. P. M., Tops, C. M. J., Romijn, J. A., Vriends, A. H. J. T., van der Mey, A. G. L., Cornelisse, C. J., Devilee, P., Bayley, J. P. High prevalence of founder mutations of the succinate dehydrogenase genes in the Netherlands. Clin. Genet. 81: 284-288, 2012. [PubMed: 21348866] [Full Text: https://doi.org/10.1111/j.1399-0004.2011.01653.x]

  27. Herrmann, J. Delayed mutation model: carotid body tumors and retinoblastoma. In: Mulvihill, J. J.; Miller, R. W.; Fraumeni, J. F., Jr.: Genetics of Human Cancer. New York: Raven Press (pub.) 1977. Pp. 417-438.

  28. Heutink, P., van der Mey, A. G. L., Sandkuijl, L. A., van Gils, A. P. G., Bardoel, A., Breedveld, G. J., van Vliet, M., van Ommen, G.-J. B., Cornelisse, C. J., Oostra, B. A., Weber, J. L., Devilee, P. A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to chromosome 11q23-qter. Hum. Molec. Genet. 1: 7-10, 1992. [PubMed: 1301144] [Full Text: https://doi.org/10.1093/hmg/1.1.7]

  29. Heutink, P., van Schothorst, E. M., van der Mey, A. G. L., Bardoel, A., Breedveld, G., Pertijs, J., Sandkuijl, L. A., van Ommen, G.-J. B., Cornelisse, C. J., Oostra, B. A., Devilee, P. Further localization of the gene for hereditary paragangliomas and evidence for linkage in unrelated families. Europ. J. Hum. Genet. 2: 148-158, 1994. [PubMed: 7834274] [Full Text: https://doi.org/10.1159/000472358]

  30. Karasov, R. S., Sheps, S. G., Carney, J. A., van Heerden, J. A., DeQuattro, V. Paragangliomatosis with numerous catecholamine-producing tumors. Mayo Clin. Proc. 57: 590-595, 1982. [PubMed: 6213823]

  31. Katz, A. D. Carotid body tumors in a large family group. Am. J. Surg. 108: 570-573, 1964. [PubMed: 14211450] [Full Text: https://doi.org/10.1016/0002-9610(64)90157-6]

  32. Khafagi, F., Egerton-Vernon, J., van Doorn, T., Foster, W., McPhee, I. B., Allison, R. W. G. Localization and treatment of familial malignant nonfunctional paraganglioma with iodine-131 MIBG: report of two cases. J. Nucl. Med. 28: 528-531, 1987. [PubMed: 2437268]

  33. Knudson, A. G., Jr. Genetics of human cancer. Annu. Rev. Genet. 20: 231-251, 1986. [PubMed: 2880556] [Full Text: https://doi.org/10.1146/annurev.ge.20.120186.001311]

  34. Kroll, A. J., Alexander, B., Cochios, F., Pechet, L. Hereditary deficiencies of clotting factors VII and X associated with carotid-body tumors. New Eng. J. Med. 270: 6-13, 1964. [PubMed: 14062129] [Full Text: https://doi.org/10.1056/NEJM196401022700102]

  35. Ladenheim, J. C., Sachs, E., Jr. Familial tumors of the 'glomus jugulare': report of 2 cases, with a note on the vascular origin of the glomera. Neurology 11: 303-309, 1961. [PubMed: 13758152] [Full Text: https://doi.org/10.1212/wnl.11.4.303]

  36. Lee, S. P., Nicholson, G. I., Hitchcock, G. C. Familial abdominal chemodectomas with associated cutaneous angiolipomas. Pathology 9: 173-177, 1977. [PubMed: 195258] [Full Text: https://doi.org/10.3109/00313027709085255]

  37. Leube, B., Huber, R., Goecke, T. O., Sandmann, W., Royer-Pokora, B. SDHD mutation analysis in seven German patients with sporadic carotid body paraganglioma: one novel mutation, no Dutch founder mutation and further evidence that G12S is a polymorphism. (Letter) Clin. Genet. 65: 61-63, 2004. [PubMed: 15032977] [Full Text: https://doi.org/10.1111/j..2004.00174.x]

  38. Mariman, E. C. M., van Beersum, S. E. C., Cremers, C. W. R. J., Struycken, P. M., Ropers, H. H. Fine mapping of a putatively imprinted gene for familial non-chromaffin paragangliomas to chromosome 11q13.1: evidence for genetic heterogeneity. Hum. Genet. 95: 56-62, 1995. [PubMed: 7814027] [Full Text: https://doi.org/10.1007/BF00225075]

  39. Masuoka, J., Brandner, S., Paulus, W., Soffer, D., Vital, A., Chimelli, L., Jouvet, A., Yonekawa, Y., Kleihues, P., Ohgaki, H. Germline SDHD mutation in paraganglioma of the spinal cord. Oncogene 20: 5084-5086, 2001. [PubMed: 11526495] [Full Text: https://doi.org/10.1038/sj.onc.1204579]

  40. Mhatre, A. N., Li, Y., Feng, L., Gasperin, A., Lalwani, A. K. SDHB, SDHC, and SDHD mutation screen in sporadic and familial head and neck paragangliomas. Clin. Genet. 66: 461-466, 2004. [PubMed: 15479192] [Full Text: https://doi.org/10.1111/j.1399-0004.2004.00328.x]

  41. Milunsky, J., DeStefano, A. L., Huang, X.-L., Baldwin, C. T., Michels, V. V., Jako, G., Milunsky, A. Familial paragangliomas: linkage to chromosome 11q23 and clinical implications. Am. J. Med. Genet. 72: 66-70, 1997. [PubMed: 9295078] [Full Text: https://doi.org/10.1002/(sici)1096-8628(19971003)72:1<66::aid-ajmg14>3.0.co;2-s]

  42. Milunsky, J. M., Maher, T. A., Michels, V. V., Milunsky, A. Novel mutations and the emergence of a common mutation in the SDHD gene causing familial paraganglioma. Am. J. Med. Genet. 100: 311-314, 2001. [PubMed: 11343322] [Full Text: https://doi.org/10.1002/ajmg.1270]

  43. Neumann, H. P. H., Pawlu, C., Peczkowska, M., Bausch, B., McWhinney, S. R., Muresan, M., Buchta, M., Franke, G., Klisch, J., Bley, T. A., Hoegerle, S., Boedeker, C. C., Opocher, G., Schipper, J., Januszewicz, A., Eng. C. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292: 943-951, 2004. Note: Erratum: JAMA 292: 1686 only, 2004. [PubMed: 15328326] [Full Text: https://doi.org/10.1001/jama.292.8.943]

  44. Nissenblatt, M. J. Cyanotic heart disease: 'low altitude' risk for carotid body tumor? Johns Hopkins Med. J. 142: 18-22, 1978. [PubMed: 625092]

  45. Oosterwijk, J. C., Jansen, J. C., van Schothorst, E. M., Oosterhof, A. W., Devilee, P., Bakker, E., Zoeteweij, M. W., van der Mey, A. G. L. First experiences with genetic counselling based on predictive DNA diagnosis in hereditary glomus tumours (paragangliomas). J. Med. Genet. 33: 379-383, 1996. [PubMed: 8733047] [Full Text: https://doi.org/10.1136/jmg.33.5.379]

  46. Parkin, J. L. Familial multiple glomus tumors and pheochromocytomas. Ann. Otol. Rhinol. Laryng. 90: 60-63, 1981. [PubMed: 6258467] [Full Text: https://doi.org/10.1177/000348948109000115]

  47. Parry, D. M., Li, F. P., Strong, L. C., Carney, J. A., Schottenfeld, D., Reimer, R. R., Grufferman, S. Carotid body tumors in humans: genetics and epidemiology. J. Nat. Cancer Inst. 68: 573-578, 1982. [PubMed: 6951072]

  48. Pigny, P., Vincent, A., Bauters, C. C., Bertrand, M., de Montpreville, V. T., Crepin, M., Porchet, N., Caron, P. Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation. J. Clin. Endocr. Metab. 93: 1609-1615, 2008. [PubMed: 18211978] [Full Text: https://doi.org/10.1210/jc.2007-1989]

  49. Pratt, L. W. Familial carotid body tumors. Arch. Otolaryng. 97: 334-336, 1973. [PubMed: 4699542] [Full Text: https://doi.org/10.1001/archotol.1973.00780010344011]

  50. Prontera, P., Ferrando, B., Giuliani, V., Falcinelli, F., Mencarelli, A., Rogaia, D., Pasini, B, Donti, E. A novel mutation in the SDHD gene responsible for familial paraganglioma. Medical and psychological implications. Genet. Counsel. 19: 413-418, 2008. [PubMed: 19239085]

  51. Resler, D. R., Snow, J. B., Williams, G. R. Multiplicity and familial incidence of carotid body and glomus jugulare tumors. Ann. Otol. Rhinol. Laryng. 75: 114-122, 1966. [PubMed: 4286420] [Full Text: https://doi.org/10.1177/000348946607500109]

  52. Rosen, S. Glomus jugulare tumor of the middle ear with normal drum, improved biopsy technique. Ann. Otol. Rhinol. Laryng. 61: 448-451, 1952. [PubMed: 14944141] [Full Text: https://doi.org/10.1177/000348945206100214]

  53. Strauchen, J. A. Germ-line mutations in nonsyndromic pheochromocytoma. (Letter) New Eng. J. Med. 347: 854-855, 2002. [PubMed: 12226162] [Full Text: https://doi.org/10.1056/NEJM200209123471117]

  54. van Baars, F., Cremers, C., van den Broek, P., Geerts, S., Veldman, J. Genetic aspects of nonchromaffin paraganglioma. Hum. Genet. 60: 305-309, 1982. [PubMed: 6286462] [Full Text: https://doi.org/10.1007/BF00569208]

  55. van der Mey, A. G., Maaswinkel-Mooy, P. D., Cornelisse, C. J., Schmidt, P. H., van de Kamp, J. J. Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet 334: 1291-1294, 1989. Note: Originally Volume II. [PubMed: 2574254] [Full Text: https://doi.org/10.1016/s0140-6736(89)91908-9]

  56. van Schothorst, E. M., Beekman, M., Torremans, P., Kuipers-Dijkshoorn, N. J., Wessels, H. W., Bardoel, A. F. J., van der Mey, A. G. L., van der Vijver, M. J., van Ommen, G.-J. B., Devilee, P., Cornelisse, C. J. Paragangliomas of the head and neck region show complete loss of heterozygosity at 11q22-q23 in chief cells and the flow-sorted DNA aneuploid fraction. Hum. Path. 29: 1045-1049, 1998. [PubMed: 9781639] [Full Text: https://doi.org/10.1016/s0046-8177(98)90411-7]

  57. van Schothorst, E. M., Jansen, J. C., Grooters, E., Prins, D. E. M., Wiersinga, J. J., van der Mey, A. G. L., van Ommen, G.-J. B., Devilee, P., Cornelisse, C. J. Founder effect at PGL1 in hereditary head and neck paraganglioma families from The Netherlands. Am. J. Hum. Genet. 63: 468-473, 1998. [PubMed: 9683583] [Full Text: https://doi.org/10.1086/301951]

  58. Wilson, H. Carotid body tumors: familial and bilateral. Ann. Surg. 171: 843-848, 1970. [PubMed: 5420930] [Full Text: https://doi.org/10.1097/00000658-197006010-00004]


Contributors:
Cassandra L. Kniffin - updated : 5/8/2013
Cassandra L. Kniffin - updated : 4/11/2012
Cassandra L. Kniffin - updated : 5/14/2010
Cassandra L. Kniffin - updated : 3/9/2010
Ada Hamosh - updated : 9/15/2009
John A. Phillips, III - updated : 2/26/2009
Cassandra L. Kniffin - updated : 1/5/2009
John A. Phillips, III - updated : 4/9/2007
Victor A. McKusick - updated : 4/28/2005
Cassandra L. Kniffin - reorganized : 1/31/2005
Cassandra L. Kniffin - updated : 1/19/2005
Victor A. McKusick - updated : 8/13/2003
Michael B. Petersen - updated : 6/23/2003
Victor A. McKusick - updated : 9/30/2002
Victor A. McKusick - updated : 2/6/2002
Victor A. McKusick - updated : 12/10/2001
Sonja A. Rasmussen - updated : 6/13/2001
Ada Hamosh - updated : 2/2/2000
Victor A. McKusick - updated : 1/10/2000
Victor A. McKusick - updated : 4/26/1999
Victor A. McKusick - updated : 1/20/1999
Victor A. McKusick - updated : 7/16/1998
Victor A. McKusick - updated : 10/3/1997
Moyra Smith - updated : 1/27/1997

Creation Date:
Victor A. McKusick : 6/2/1986

Edit History:
carol : 10/17/2023
ckniffin : 10/11/2023
carol : 04/21/2023
alopez : 06/24/2019
alopez : 06/21/2019
ckniffin : 06/14/2019
carol : 08/23/2016
carol : 05/23/2016
carol : 5/20/2013
ckniffin : 5/8/2013
alopez : 4/13/2012
alopez : 4/13/2012
terry : 4/11/2012
ckniffin : 4/11/2012
wwang : 8/16/2011
ckniffin : 8/15/2011
wwang : 5/24/2010
ckniffin : 5/14/2010
wwang : 4/7/2010
ckniffin : 3/9/2010
alopez : 9/17/2009
terry : 9/15/2009
alopez : 2/26/2009
terry : 2/6/2009
wwang : 2/5/2009
ckniffin : 1/5/2009
carol : 4/9/2007
carol : 5/1/2006
tkritzer : 5/12/2005
terry : 4/28/2005
carol : 1/31/2005
ckniffin : 1/19/2005
ckniffin : 3/23/2004
carol : 3/9/2004
tkritzer : 2/27/2004
cwells : 11/6/2003
tkritzer : 8/18/2003
terry : 8/13/2003
cwells : 6/23/2003
mgross : 10/1/2002
carol : 9/30/2002
ckniffin : 5/15/2002
alopez : 2/6/2002
carol : 12/10/2001
mcapotos : 6/13/2001
mcapotos : 6/13/2001
alopez : 10/31/2000
alopez : 2/3/2000
terry : 2/2/2000
mgross : 1/10/2000
carol : 11/8/1999
mgross : 5/12/1999
terry : 5/5/1999
mgross : 4/28/1999
terry : 4/26/1999
carol : 1/29/1999
terry : 1/20/1999
carol : 12/15/1998
terry : 8/5/1998
terry : 7/16/1998
jenny : 10/7/1997
terry : 10/3/1997
mark : 2/12/1997
mark : 2/12/1997
terry : 2/5/1997
terry : 1/27/1997
mark : 1/24/1997
mark : 7/9/1996
terry : 6/28/1996
terry : 3/3/1995
carol : 2/6/1995
mimadm : 1/14/1995
pfoster : 4/27/1994
warfield : 4/12/1994
carol : 7/12/1993